文献速递浆细胞疾病

MOR202(新型抗CD38单克隆抗体)治疗复发或难治性多发性骨髓瘤:首次人体多中心1-2a期试验

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
PubMed 文献 · Lancet Haematol · 2020-03-11

MOR202静脉输注30分钟内可安全给药,未达到最大耐受剂量,推荐方案为MOR202 up to 16 mg/kg联合地塞米松或联合地塞米松+来那度胺/泊马度胺。常见≥3级治疗中出现的不良事件为淋巴细胞减少、中性粒细胞减少和白细胞减少,未检测到抗MOR202抗体。

要点

  • MOR202静脉输注30分钟内可安全给药,未达到最大耐受剂量。
  • 推荐方案为MOR202 up to 16 mg/kg联合地塞米松或联合地塞米松+来那度胺/泊马度胺。
  • 常见≥3级不良事件为淋巴细胞减少、中性粒细胞减少和白细胞减少。

核心结论

  • MOR202在复发或难治性多发性骨髓瘤患者中安全,临床活性有前景。
  • 建议进一步开展与免疫调节药物和地塞米松联合的临床研究。

研究设计与样本

  • 纳入91例年龄≥18岁、复发或难治性多发性骨髓瘤且Karnofsky体能状态≥60%的患者。
  • 主要终点为安全性、MOR202最大耐受剂量(或推荐剂量)和方案、免疫原性,在安全性人群中分析。

主要发现

  • 2011年8月24日至2017年8月1日,91例患者接受治疗:35例MOR202单药,56例联合方案(18例联合地塞米松,21例联合地塞米松+泊马度胺,17例联合地塞米松+来那度胺)。
  • MOR202静脉输注可在30分钟内安全给药。
  • 输注相关反应在未用地塞米松的MOR202单药组35例中发生14例(40%),在联合治疗组56例中发生4例(7%)。
  • MOR202最大耐受剂量未达到;推荐方案为MOR202 30分钟静脉输注,剂量up to 16 mg/kg,联合地塞米松(40 mg),或联合地塞米松+来那度胺(25 mg)或泊马度胺(4 mg)。
  • 91例中常见≥3级治疗中出现的不良事件:淋巴细胞减少35例(38%)、中性粒细胞减少30例(33%)、白细胞减少27例(30%);严重不良事件51例(56%)。

关键数值与推荐

  • 推荐方案:MOR202 30分钟静脉输注,剂量up to 16 mg/kg,联合地塞米松40 mg,或联合地塞米松+来那度胺25 mg或泊马度胺4 mg。
  • MOR202最大耐受剂量未达到。
  • 未检测到抗MOR202抗体。

临床怎么用

  • MOR202可在30分钟内静脉输注给药,联合地塞米松或地塞米松+免疫调节药物(来那度胺或泊马度胺)为推荐方案。
  • 治疗期间需监测淋巴细胞减少、中性粒细胞减少和白细胞减少等≥3级不良事件。
  • 联合方案中输注相关反应发生率低于单药未用地塞米松方案(7% vs 40%)。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival. To further explore this therapeutic approach, we investigated the safety and activity of MOR202, a novel monoclonal antibody targeting CD38, in patients with multiple myeloma. METHODS: This is a multicentre, open-label, phase 1-2a trial done at ten hospitals in Germany and Austria. Enrolled patients were aged 18 years or older with relapsed or refractory multiple myeloma and Karnofsky performance status of 60% or higher. Patients were assigned to the different treatment regimens with MOR202 ranging between 0·01 mg/kg and 16 mg/kg in a 3 + 3 design. Dose-escalation and expansion was done either with MOR202 intravenous infusions alone (MOR202 q2w [twice a week] and q1w [weekly] groups) or in combination with dexamethasone (MOR202 with dexamethasone group), with dexamethasone plus pomalidomide (MOR202 with dexamethasone plus pomalidomide group) or plus lenalidomide (MOR202 with dexamethasone plus lenalidomide group). Primary endpoints were safety, MOR202 maximum tolerated dose (or recommended dose) and regimen, and immunogenicity. The primary analysis was assessed in the safety population, which included patients who received at least one dose of any study drug. This trial is registered with ClinicalTrials.gov, NCT01421186. FINDINGS: Between Aug 24, 2011, and Aug 1, 2017, 91 patients were treated, 35 with MOR202 monotherapy, and 56 with MOR202 combination regimens (18 in the MOR202 with dexamethasone group, 21 in the MOR202 with dexamethasone plus pomalidomide group, and 17 in the MOR202 with dexamethasone plus lenalidomide group). MOR202 intravenous infusions were safely administered within 30 min. Infusion-related reactions occurred in 14 (40%) of 35 patients receiving MOR202 monotherapy without steroids, and in four (7%) of 56 patients receiving MOR202 combination treatment. MOR202 maximum tolerated dose was not reached and the recommended regimens were MOR202 administered as an intravenous infusion for 30 min at doses up to 16 mg/kg with dexamethasone (40 mg), or in combination with dexamethasone plus lenalidomide (25 mg) or pomalidomide (4 mg). 35 (38%) of 91 patients developed lymphopenia, 30 (33%) developed neutropenia, and 27 (30%) developed leukopenia; these were the most common grade 3 or higher treatment-emergent adverse events. Serious adverse events were reported in 51 (56%) of 91 patients. None of the deaths were associated with MOR202. One pomalidomide-associated death occurred in the MOR202 with dexamethasone plus pomalidomide group. No anti-MOR202 antibodies were detected in patients. INTERPRETATION: MOR202 is safe and its clinical activity in patients with relapsed or refractory multiple myeloma is promising. Further clinical investigations of combinations with an immunomodulatory drug and dexamethasone are recommended. FUNDING: MorphoSys AG.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Raab MS, Engelhardt M, Blank A, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020. PMID: 32171061. doi:10.1016/S2352-3026(19)30249-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。